Back to Journals » Cancer Management and Research » Volume 10

A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer

Authors Wang X, Zhou J, Xu M, Yan Y, Huang L, Kuang Y, Liu Y, Li P, Zheng W, Liu H, Jia B

Received 29 June 2018

Accepted for publication 27 September 2018

Published 16 November 2018 Volume 2018:10 Pages 5799—5806

DOI https://doi.org/10.2147/CMAR.S178732

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Professor Nakshatri


Xuning Wang,1 Jianguo Zhou,2 Maolin Xu,1 Yongfeng Yan,3 Liang Huang,1 Yanshen Kuang,1 Yuansheng Liu,4 Peng Li,3 Wei Zheng,3 Hongyi Liu,3 Baoqing Jia3

1Department of General Surgery, Chinese PLA Medical School, Beijing 100853, People’s Republic of China; 2Division of Thoracic Oncology, Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi City 563000, Guizhou Province, People’s Republic of China; 3Department of General Surgery, Chinese PLA General Hospital, Beijing 100853, People’s Republic of China; 4School of Medicine, Nankai University, TianJing, People’s Republic of China

Purpose: Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. This study aimed to explore the prognostic value of lncRNAs in CRC.
Material and methods: We performed gene expression profiling to identify differentially expressed lncRNAs between 51 normal and 646 tumor tissues from The Cancer Genome Atlas database. Cox regression and robust likelihood-based survival models were used to find prognosis-related lncRNAs. A lncRNA signature was developed to predict the overall survival of patients with CRC. In addition, a receiver operating characteristic curve analysis was performed to identify the optimal cutoff with the best Youden index to divide patients into different groups based on risk level.
Results: Eighty survival-related lncRNAs were identified and a 15-lncRNA signature was developed on the basis of a risk score to comprehensively predict the overall survival of patients with CRC. The prognostic value of the 15-lncRNA risk score was validated using the internal testing set and total set. The risk indicator was shown to be an independent prognostic factor (hazard ratio =2.92; 95% CI: 1.73–4.94; P<0.001). Notably, all 15 lncRNAs (AC024581.1, FOXD3-AS1, AC012531.1, AC003101.2, LINC01219, AC083967.1, AL590483.1, AC105118.1, AC010789.1, AC067930.5, AC105219.2, LINC01354, LINC02474, LINC02257, and AC079612.1) were newly found to correlate with the prognosis of patients with CRC. Furthermore, the function of 15 lncRNAs was explored through the ceRNA network. These lncRNAs regulated coding genes that were involved in many key cancer pathways.
Conclusion: A 15-lncRNA expression signature was discovered as a prognostic indicator for patients with CRC, which may act as competing endogenous RNA (ceRNAs) to play a crucial role in the modulation of cancer-related pathways. These findings may allow a better understanding of the prognostic value of lncRNAs.

Keywords: long noncoding RNA, colorectal cancer, survival, biomarker, competing endogenous RNA, ceRNA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]